Structure based predictive modeling
US-2015134315-A1 · May 14, 2015 · US
US10793836B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10793836-B2 |
| Application number | US-201916443250-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jun 17, 2019 |
| Priority date | Nov 25, 2014 |
| Publication date | Oct 6, 2020 |
| Grant date | Oct 6, 2020 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
The present application provides engineered polypeptides having imine reductase activity, polynucleotides encoding the engineered imine reductases, host cells capable of expressing the engineered imine reductases, and methods of using these engineered polypeptides with a range of ketone and amine substrate compounds to prepare secondary and tertiary amine product compounds.
Opening claim text (preview).
What is claimed is: 1. A polynucleotide encoding an engineered polypeptide, wherein the engineered polypeptide comprises an amino acid sequence with at least 90% sequence identity to the reference sequence of SEQ ID NO:8, wherein the alanine at the position corresponding to amino acid 239 of SEQ ID NO:8 is substituted with another amino acid in the amino acid sequence of the engineered polypeptide, and wherein the engineered polypeptide has imine reductase activity. 2. A polynucleotide encoding an engineered polypeptide, wherein the engineered polypeptide comprises an amino acid sequence with at least 90% sequence identity to the reference sequence of SEQ ID NO:8, wherein the isoleucine at the position corresponding to amino acid 330 of SEQ ID NO:8 is substituted with another amino acid in the amino acid sequence of the engineered polypeptide, wherein the amino acid sequence of the engineered polypeptide has a valine, threonine, tryptophan, glutamic acid, or tyrosine at the position corresponding to amino acid 283 of SEQ ID NO:8, and wherein the engineered polypeptide has imine reductase activity. 3. The polynucleotide of claim 2 , wherein the amino acid sequence of the engineered polypeptide comprises at least one residue difference as compared to the reference sequence of SEQ ID NO:4, wherein the at least one residue difference is at a residue selected from the group consisting of 198, 153, 167, 265, 262, 108, 234, 284, 282, 220, 272, 256, 267, 242, 281, 197, 277, 224, and 143, and wherein the residue number corresponds to the amino acid sequence of SEQ ID NO:4. 4. The polynucleotide of claim 2 , wherein the amino acid sequence of the engineered polypeptide comprises at least one residue difference as compared to the reference sequence of SEQ ID NO:6, wherein the at least one residue difference is at a residue selected from the group consisting of 262, 9, 259, 220, 267, 153, 279, 200, 224, 256, 137, 143, 260, 261, 154, 276, and 185, and wherein the residue number corresponds to the amino acid sequence of SEQ ID NO:6. 5. The polynucleotide of claim 2 , wherein the amino acid sequence of the engineered polypeptide further comprises at least one residue difference as compared to the reference sequence of SEQ ID NO:8, wherein the at least one residue difference is at a residue selected from the group consisting of 12, 31, 37, 44, 46, 48, 55, 56, 65, 82, 93, 98, 108, 137, 138, 141, 142, 143, 153, 154, 155, 156, 159, 166, 168, 173, 177, 178, 184, 185, 195, 197, 199, 200, 201, 203, 205, 206, 210, 213, 215, 216, 218, 220, 221, 223, 226, 234, 239, 242, 245, 251, 253, 256, 257, 259, 260, 261, 262, 263, 265, 266, 267, 268, 269, 273, 274, 277, 278, 279, 280, 281, 282, 284, 285, 289, 290, 291, 292, 293, 294, and 349, and wherein the residue number corresponds to the amino acid sequence of SEQ ID NO:8. 6. The polynucleotide of claim 2 , wherein the imine reductase activity comprises converting the ketone substrate and the amine substrate to produce the amine product compound under suitable reaction conditions. 7. The polynucleotide of claim 6 , wherein the imine reductase activity in converting the ketone and the amine substrate compound to the amine product compound under suitable reaction conditions is increased at least 2-fold as compared to the corresponding activity of an imine reductase polypeptide comprising the amino acid sequence of SEQ ID NO: 4, 6, 12, 30, 126, 173, 360, or 550. 8. The polynucleotide of claim 1 , wherein the amino acid sequence of the engineered polypeptide comprises SEQ ID NO: 1188. 9. An expression vector comprising the polynucleotide of claim 1 . 10. An expression vector comprising the polynucleotide of claim 2 . 11. An isolated host cell comprising the polynucleotide of claim 1 . 12. An isolated host cell comprising the polynucleotide of claim 2 . 13. An isolated host cell comprising the expression vector of claim 9 . 14. An isolated host cell comprising the expression vector of claim 10 . 15. A method of preparing an engineered polypeptide having imine reductase activity, comprising culturing the host cell of claim 11 , under conditions suitable for expression of the engineered polypeptide, and optionally further comprising isolating the engineered polypeptide.
with NAD or NADP as acceptor (1.5.1) · CPC title
Amines; Imines · CPC title
from bacteria · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.